HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
Hashem E El-SeragQingchun JinNabihah TayobEmad SalemMichelle LusterAbeer AlsarrajSaira KhaderiAmit G SingalJorge A MarreroSumeet K AsraniFasiha KanwalPublished in: Hepatology (Baltimore, Md.) (2024)
In a prospective cohort study, HES V2.0 had a significantly higher performance for identifying new HCC, including early stage, than GALAD or ASAP.